^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PhOx430

    i
    Other names: PhOx430, PhOx 430, PhOx-430
    Associations

    News

    Trials
    Company:
    Phost'IN
    Drug class:
    GnT-V inhibitor
    Associations

    News

    Trials
    over1year
    PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=149, Recruiting, Phost'In Therapeutics | Trial primary completion date: Jul 2024 --> Nov 2024
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    PhOx430
    almost2years
    PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=149, Recruiting, Phost'In Therapeutics | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Jun 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    PhOx430
    over3years
    PhAST: First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=146, Recruiting, Phost'In Therapeutics
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • HER-2 negative
    |
    PhOx430